Vanderlinden, Greet http://orcid.org/0000-0002-5673-4121
Carron, Charles
Vandenberghe, Rik
Vandenbulcke, Mathieu
Van Laere, Koen
Funding for this research was provided by:
Stichting Alzheimer Onderzoek (SAO-FRA 2021/0004)
Article History
Received: 28 August 2023
Accepted: 5 February 2024
First Online: 12 February 2024
Declarations
:
: Study approval has been obtained by the ethics committee at the University Hospitals Leuven (local study number S66611) and by the Belgian competent authority (federal agency for medicines and health products). It will be conducted in accordance with the latest version of the Declaration of Helsinki as well as the Good Clinical Practice guidelines and all applicable regulatory requirements. The collection, processing and disclosure of personal data, such as patient health and medical information is subject to compliance with applicable personal data protection and the processing of personal data (Regulation (EU) 2016/679 also referred as the General Data Protection Regulation (“GDPR”) and the Belgian Law of July 30, 2018, on the protection of natural persons with regard to the processing of personal data). Written informed consent will be obtained from all participants (or their legal representative in case of patients who are unable to give consent themselves) prior to study inclusion.
: Not applicable since individual person’s data was not used.
: K.V.L. has performed contract research through KU Leuven for Merck, Janssen Pharmaceuticals, UCB, Cerveau, Syndesi, Eikonizo, GE Healthcare and Curasen. G.V., C.C., R.V. and M.V. report no competing interests.
: The study is currently ongoing, and recruitment of study participants has started. Data collection has commenced and is estimated to be completed late 2024.